Tags

Type your tag names separated by a space and hit enter

Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
Stroke 2018; 49(9):2129-2137S

Abstract

Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL). SISTERS (Spasticity In Stroke-Randomized Study) was a randomized, controlled, open-label, multicenter, phase 4 study to evaluate ITB therapy versus conventional medical management (CMM) with oral antispastic medications for treatment of poststroke spasticity. Methods- Poststroke patients with spasticity in ≥2 extremities and an Ashworth Scale score of ≥3 in ≥2 affected lower extremity muscle groups were randomized (1:1) to ITB (N=31) or CMM (N=29). Both treatment arms received physiotherapy throughout. The primary outcome was the change in average Ashworth Scale score in the lower extremities of the affected side from baseline to month 6. Here, we report results for secondary outcomes: pain via the Numeric Pain Rating Scale, health-related QoL by the EuroQol-5 dimensional 3 level utility score and health status visual analog scale score, stroke-specific QoL, and patient satisfaction. Analyses were performed on an intention-to-treat basis. Results- We observed significant treatment effects in favor of ITB over CMM for changes from baseline to month 6 in Numeric Pain Rating Scale scores for actual pain (ITB versus CMM: mean, -1.17 [SD, 3.17] versus 0.00 [3.29]; median, -1.00 versus 0.00; P=0.0380) and least pain (mean, -1.61 [2.29] versus 0.24 [3.07]; median, -1.00 versus 0.00; P=0.0136), and EuroQol-5 dimensional 3 level utility scores (mean, +0.09 [0.26] versus +0.01 [0.16]; median, +0.07 versus 0.00; P=0.0197). Between-group differences were not statistically significant for EuroQol-5 dimensional 3 level visual analog scale, stroke-specific QoL summary, or Numeric Pain Rating Scale worst pain scores, although ITB patients showed greater numeric improvements from baseline during follow-up. More ITB patients than CMM patients (73% versus 48%) were satisfied with the spasticity reduction at month 6. Conclusions- These data support that ITB therapy is associated with improvements in pain and QoL in poststroke patients. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01032239.

Authors+Show Affiliations

From the Central Florida Pain Relief Centers, Orlando (M.C.).St. George's University Hospitals NHS Foundation Trust, London, United Kingdom (G.C.). Department of Neurology, Alfred Health, Melbourne, VIC, Australia (G.C.).Kliniken Beelitz GmbH Neurologische Rehabilitationsklinik, Beelitz-Heilstätten, Germany (P.K.).MedStar National Rehabilitation Hospital, Washington, DC (M.Y.). Shepherd Center, Atlanta, GA (M.Y.).Department of Physical Medicine and Rehabilitation, University of Texas Health Science Center and TIRR Memorial Hermann Hospital, Houston (G.E.F.).North Staffordshire Rehabilitation Centre, Haywood Hospital, Stoke-On-Trent, United Kingdom (A.B.W.).Neurological Rehabilitation and Physical Therapy, Department of Neurology, Vivantes Hospital Spandau, Berlin, Germany (J.W.).USL Umbria 2, Department of Rehabilitation, Ospedale di Foligno, Perugia, Italy (M.Z.).Neuromodulation Clinical, Medtronic International, Tolochenaz, Switzerland (A.A., A.C.).Neuromodulation Clinical, Medtronic International, Tolochenaz, Switzerland (A.A., A.C.).Abteilung für Neurologie Landeskrankenhaus Hochzirl, Austria (L.S.). Research Unit for Neurorehabilitation South Tyrol, Bolzano, Italy (L.S.).

Pub Type(s)

Clinical Trial, Phase IV
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30354975

Citation

Creamer, Michael, et al. "Effect of Intrathecal Baclofen On Pain and Quality of Life in Poststroke Spasticity." Stroke, vol. 49, no. 9, 2018, pp. 2129-2137.
Creamer M, Cloud G, Kossmehl P, et al. Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. Stroke. 2018;49(9):2129-2137.
Creamer, M., Cloud, G., Kossmehl, P., Yochelson, M., Francisco, G. E., Ward, A. B., ... Saltuari, L. (2018). Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. Stroke, 49(9), pp. 2129-2137. doi:10.1161/STROKEAHA.118.022255.
Creamer M, et al. Effect of Intrathecal Baclofen On Pain and Quality of Life in Poststroke Spasticity. Stroke. 2018;49(9):2129-2137. PubMed PMID: 30354975.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. AU - Creamer,Michael, AU - Cloud,Geoffrey, AU - Kossmehl,Peter, AU - Yochelson,Michael, AU - Francisco,Gerard E, AU - Ward,Anthony B, AU - Wissel,Jörg, AU - Zampolini,Mauro, AU - Abouihia,Abdallah, AU - Calabrese,Alessandra, AU - Saltuari,Leopold, PY - 2018/10/26/entrez PY - 2018/10/26/pubmed PY - 2019/10/15/medline KW - baclofen KW - muscle spasticity KW - pain KW - quality of life KW - stroke SP - 2129 EP - 2137 JF - Stroke JO - Stroke VL - 49 IS - 9 N2 - Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL). SISTERS (Spasticity In Stroke-Randomized Study) was a randomized, controlled, open-label, multicenter, phase 4 study to evaluate ITB therapy versus conventional medical management (CMM) with oral antispastic medications for treatment of poststroke spasticity. Methods- Poststroke patients with spasticity in ≥2 extremities and an Ashworth Scale score of ≥3 in ≥2 affected lower extremity muscle groups were randomized (1:1) to ITB (N=31) or CMM (N=29). Both treatment arms received physiotherapy throughout. The primary outcome was the change in average Ashworth Scale score in the lower extremities of the affected side from baseline to month 6. Here, we report results for secondary outcomes: pain via the Numeric Pain Rating Scale, health-related QoL by the EuroQol-5 dimensional 3 level utility score and health status visual analog scale score, stroke-specific QoL, and patient satisfaction. Analyses were performed on an intention-to-treat basis. Results- We observed significant treatment effects in favor of ITB over CMM for changes from baseline to month 6 in Numeric Pain Rating Scale scores for actual pain (ITB versus CMM: mean, -1.17 [SD, 3.17] versus 0.00 [3.29]; median, -1.00 versus 0.00; P=0.0380) and least pain (mean, -1.61 [2.29] versus 0.24 [3.07]; median, -1.00 versus 0.00; P=0.0136), and EuroQol-5 dimensional 3 level utility scores (mean, +0.09 [0.26] versus +0.01 [0.16]; median, +0.07 versus 0.00; P=0.0197). Between-group differences were not statistically significant for EuroQol-5 dimensional 3 level visual analog scale, stroke-specific QoL summary, or Numeric Pain Rating Scale worst pain scores, although ITB patients showed greater numeric improvements from baseline during follow-up. More ITB patients than CMM patients (73% versus 48%) were satisfied with the spasticity reduction at month 6. Conclusions- These data support that ITB therapy is associated with improvements in pain and QoL in poststroke patients. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01032239. SN - 1524-4628 UR - https://www.unboundmedicine.com/medline/citation/30354975/Effect_of_Intrathecal_Baclofen_on_Pain_and_Quality_of_Life_in_Poststroke_Spasticity_ L2 - http://www.ahajournals.org/doi/full/10.1161/STROKEAHA.118.022255?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -